Biologics developers are caught in a paradox: demand for therapies is climbing, but the industry faces constant pressure to cut costs and move faster. For upstream process scientists, the challenge is to make more product with fewer resources—and do it on accelerated timelines.

A promising solution is intensified fed-batch processing, which integrates perfusion-enabled seeding with streamlined feeding strategies. Compared to conventional fed-batch, this approach can deliver five to ten times more productivity while reducing production costs and facility size, according to Yuxin Liu, PhD, a senior scientist in culture development at Sanofi, who spoke at this week’s Bioprocess International Conference in Boston.

Recent work with an intensified fed-batch platform shows what’s possible. By adopting high-density seeding and moving from daily VCD-based adjustments to a fixed-volume feeding strategy, titers increased from 7 g/L to 18 g/L in just 14 days, she said, adding that the fixed-volume approach not only boosted yields but also simplified operations. Teams know exactly how much feed to add from the start, eliminating the need for daily cell counts and reducing variability across runs, continued Liu.

Benefits and challenges

Liu pointed out the benefits of intensified fed-batch:

• Higher productivity with fewer batches, supporting accelerated clinical pipelines.
• Lower costs and smaller facility footprints.
• Faster timelines for early market access.

But there are hurdles. High-density cultures put new demands on media, requiring precise nutrient balance, solubility, and stability. Early trials revealed issues such as lactate buildup, amino acid depletion, and variable quality at harvest.

To address this, said Liu, new feed formulations were developed with optimized amino acid profiles, added nucleotides and antioxidants, and improved redox balance. These changes supported higher productivity while maintaining product quality.

Perhaps most importantly, she suggested, the streamlined feeding strategy reduces complexity for manufacturing teams. By eliminating daily sampling and adjustments, it saves time, cuts labor, and improves reproducibility at scale. Taken together, noted Liu, these advances signal more than incremental progress. Intensified fed-batch represents a game-changing shift in upstream bioprocessing—one that can deliver higher efficiency, faster development, and a stronger path to market for biologics.